

SUPPORT | RESEARCH | AWARENESS



# MPS VII

## Sly disease

Information for individuals,  
parents and families

Society for Mucopolysaccharide Diseases  
[mpssociety.org.uk](http://mpssociety.org.uk)

# In this booklet

- 3 What is MPS VII?
- 4 How is MPS VII inherited?
- 5 How is MPS VII diagnosed?
- 6 Is there a test for MPS VII in pregnancy?
- 7 What are the possible symptoms and how are they managed?
- 15 Living with MPS VII Sly
- 16 Support and Advocacy Lead, Steve Cotterell, shares his story
- 18 What kind of treatments and therapies are available for MPS VII?
- 19 Where can I get more information and support?

*There is huge variability within this condition. Some people may experience only some of the symptoms while the severity of those symptoms can also vary.*

This booklet is produced by the **Society for Mucopolysaccharide Diseases (MPS Society)** and is designed to help those affected by MPS VII Sly and their families understand its causes and effects. While there is currently no cure for individuals affected by MPS VII, this booklet explores how best to understand and manage the disease. It draws on the experiences of patients, carers, families and medical professionals as well as medical literature.

MPS VII disease was first identified by Dr Sly in 1972

# What is MPS VII?

**MPS VII, known as Sly disease, is a mucopolysaccharide disease. Mucopolysaccharides, also called glycosaminoglycans (GAGs), are long chains of sugar molecules used to build bones, cartilage, skin, tendons and other tissues in the body.**

**Glycosaminoglycans (GAGs)** used to be called mucopolysaccharides, which is why these diseases are known as mucopolysaccharide diseases

**Muco** means jelly-like  
**poly** means many  
**saccharides** means sugar

In the course of normal life there is a continuous recycling process which consists of building new materials and breaking down old ones ready for disposal. This breakdown and recycling process takes place in a special part of the body's cells called the lysosomes, which is why MPS VII and other similar conditions are also known as lysosomal storage diseases. The process requires a series of special biochemical tools called enzymes.

## What causes MPS VII?

MPS VII Sly disease is the result of a specific enzyme (beta-glucuronidase) either not working correctly or not being produced at all. This occurs because there is a mistake (mutation) in the gene called beta-glucuronidase (GUSB) that gives the body the instructions for making the enzyme.

This enzyme is essential in breaking down large sugar molecules called GAGs. When these are not completely broken down they remain stored in the body's cells and accumulate in many tissues and organs. The symptoms of MPS VII are a result of the build-up of dermatan sulphate, heparan sulphate

and chondroitin sulphate in the body. In general, the severity of MPS VII is related to the level of GUSB activity that remains.

**Higher enzyme activity levels** lead to less build up of dermatan sulphate, heparan sulphate and chondroitin sulphate within the body, resulting in milder signs and symptoms (sometimes called **attenuated disease**).

**Lower or absent enzyme activity levels** lead to build up of dermatan sulphate, heparan sulphate and chondroitin sulphate within the body, resulting in prominent signs and symptoms of MPS VII.

## What can I expect in the future?

It is important to note that people affected by MPS VII may not experience all the symptoms. Where symptoms are present, they vary in severity from one person to another. In the most severe form, babies may develop excess fluid (hydrops) while still in the womb, which can be rapidly fatal.

The life expectancy depends on the severity of symptoms. Severely affected people may live only until early childhood or adolescence, those with milder forms usually live into adulthood although their life expectancy may be reduced.



# How is MPS VII inherited?

**Genes** are the unique set of instructions inside our bodies that make each of us an individual

## How common is MPS VII?


It is estimated that MPS VII affects less than 1 in 1,000,000 newborns affecting males and females equally.

We have thousands of **genes** and they are the blueprint for our growth and development, as well as controlling how our bodies function. If a particular gene is faulty, or altered, then it will not work efficiently.

Genes are carried on structures called chromosomes. It is usual to have 23 pairs of chromosomes that are numbered in pairs from pair 1 to pair 22, plus one pair of sex chromosomes; XX for a female and XY for a male. A child will inherit one set of chromosomes from the mother in the egg, and one set from the father in the sperm, therefore we each have two copies of each gene, one of which is inherited from each parent.

In a person with MPS VII, both copies of the associated gene in each cell have mutations (mistakes). The parents each carry one copy of the mutated gene, but they do not show signs and symptoms of the disease. This is known as being a **carrier**.

A **carrier** will not show symptoms but can pass the defective gene to their child



## Autosomal recessive

- Affected by the disease 25%
- Carriers of affected gene 50%
- Unaffected by the disease 25%



When both parents are carriers of the faulty MPS VII gene (autosomal recessive) for each pregnancy there is a 25% (1:4) chance of having a child with MPS VII. The chance of a baby inheriting MPS VII is the same for every pregnancy.

Brothers and sisters of a person affected by MPS VII might also be carriers of the disease and it is recommended that they seek advice from their local genetic department about the potential risks in future pregnancies.

Autosomal recessive pattern is when both parents are carriers of the defective gene

## How is MPS VII diagnosed?

MPS VII diagnosis can take some time and typically requires looking at the person's medical history, symptoms and carrying out a physical exam and laboratory tests in order to make a diagnosis. People with MPS VII may experience some or all the symptoms that are outlined in this booklet before receiving an actual diagnosis.

### How is MPS VII tested?

Diagnosis of MPS VII is usually a two-stage process: a screen test and a confirmation test.

- A urine analysis will usually show excessive amounts of dermatan sulphate, heparan sulphate and chondroitin sulphate present in the urine.
- Reduced enzyme activity from a blood test or a genetic test to identify the GUSB gene mutation will then be done to confirm the diagnosis.

There is no cure for MPS VII, but treatment in the form of **ERT** works to restore cell function and can help improve physical endurance.

There is a genetic test that can be used to confirm whether or not a person has MPS VII

Enzyme replacement therapy (ERT) is available in MPS VII

# Is there a test for MPS VII in pregnancy?



**Amniocentesis** involves testing a small sample of amniotic fluid

**Chorionic villus sampling** involves testing a small sample of cells from where the placenta attaches to the uterus

**In utero** means that the tests are done while the baby is still in the womb

A **pre-implantation genetic diagnosis (PGD)** is an assisted fertility treatment

**In vitro** literally means 'in the glass', as the testing is done in a flat glass dish called a petri dish

Unless there is a known genetic risk of MPS VII in the foetus, it is unlikely that a test in pregnancy would be done. If you have a child with MPS VII or a known history in your family, it is possible to have tests during any subsequent pregnancy to find out whether the foetus is affected. It is important to contact your doctor as soon as you suspect that you may be pregnant if you wish for tests to be arranged. Both amniocentesis and chorionic villus sampling can be used to diagnose MPS VII **in utero**.

It might also be possible to have PGD screening to avoid passing MPS VII to the baby. PGD is an assisted fertility treatment that involves checking the chromosomes of embryos **in vitro** before they are implanted in the womb, using IVF techniques. This is a complex process and requires referral from your regional genetics service.

## What is the value of genetic screening and counselling?

MPS VII is a genetically inherited disease and there is a risk of recurrence in future pregnancies for a couple with an affected child. Therefore, all parents of children with MPS VII should consider asking for genetic counselling before having other children. The counsellor should be able to provide non-directive advice on the reproductive choices, the risk to close relatives, and to suggest whether the wider family should be informed.

There are several specialist centres in the UK where you can go to be tested and to see a specialist in MPS VII. The most up to date list can be found on the MPS website: [mppsociety.org.uk/our-friends](https://mppsociety.org.uk/our-friends)

# What are the possible symptoms and how are they managed?

Symptoms are known as clinical presentations

**It is important to note that people affected by MPS VII may not experience all the symptoms. Where symptoms are present, they vary in severity from one person to another.**

MPS VII signs and symptoms can be broadly described into two categories, skeletal or non-skeletal.

Skeletal symptoms are usually among the first symptoms to develop and are broadly split into the spinal region and other joints in the body.

*Sly disease may cause intellectual disabilities for people on the severe end of the spectrum*



## Our goals for 2019-2021

The future for the MPS Society is one where we put our members at the centre of everything we do in line with our vision for all people affected by our diseases to live the lives they want. In order to achieve this we have set ourselves six goals.

### Our goals

1. Affected people know where to turn for specialist knowledge, support and advocacy
2. Provide the services that beneficiaries tell us they need, in a way that suits them
3. Take an active role in research
4. Families receive the fastest possible diagnosis
5. Champion new and existing treatments and therapies
6. Making it happen by investing in our future.

# Spine and neck

**Spinal involvement is common and spine abnormalities can include weakness in the neck and skeletal deformities.**

## Development and symptoms

The **cervical spine** (neck region) is often very underdeveloped, making the neck unstable and putting the spinal cord at risk. Where the spinal cord is compressed or squeezed, there may be gradual worsening of nerve damage if left untreated.

This can lead to several problems.

- A gradual loss of power in arms and legs
- Unsteady gait
- Problems with urinary function
- Lower back pain
- Paralysis and even death in extreme cases

The bones of the **spinal column** (vertebrae) often have poorly formed bones that may not stably rest on top of each other. This can lead to short stature and curvature of the spine.

- **Scoliosis** – when the spine curves to one side
- **Kyphosis** – a hump on the upper back
- **Kyphoscoliosis** – a mixture of both scoliosis and kyphosis

The breastbone continues to grow normally but, as it is joined to the spine, it is forced to buckle outwards in a rounded curve and the chest appears **bell-shaped**.

A **bell-shaped** chest reduces breathing, making it difficult to cope well with chest infections

## Testing and management

Magnetic resonance imaging (MRI) or x-rays are performed to monitor the development and progress of the disease. **Cervical fusion** surgery can be performed under the review and management of neurosurgeons. Skeletal involvement is progressive and typically requires multiple orthopaedic interventions to prevent malformations and to improve function.

A **cervical fusion** means fusing some bones of the spine to prevent possible damage to the spinal cord

People with MPS VII  
Sly disease often have  
an abnormal way of  
walking (gait), standing  
and walking with their  
knees and hips flexed

The **cervical vertebrae** are the bones in the neck




# Joints

Joint stiffness leads to limited movement in many areas of the body, including the shoulders, arms, hips and knees, and can sometimes cause aches and pain. Movement throughout the body is affected and increased muscle weakness compromises mobility. Some people with MPS VII may need to use walking aids or become wheelchair-bound by adolescence.

## Symptoms

Physical issues with the joints are most prevalent and are often seen before diagnosis. This diagram shows the areas of the body where the joints are affected.



## Management

- Limited joint movement can make everyday activities like dressing difficult. Choose items of clothing that are easy to put on and take off to make getting dressed easier.
- Pain in the joints is a major symptom of MPS VII, there are many ways this can be managed. For some people, pain may be relieved by applying warmth to the area, for example with a heat pack. Another option is painkillers. Speak with your doctor to select the most suitable treatment.
- There are alternative therapies, such as hydrotherapy and physiotherapy programmes, speak to a healthcare professional for advice.
- Knock knees can be treated with an operation. If the child is still growing this might involve **guided growth surgery**, or if the child has stopped growing other surgery may be needed.

There are many treatments available to manage pain, so speak to your doctor about options

# Physical appearance

## Growth and height

- Babies grow normally until 18 months, thereafter growth slows significantly.
- Children who are severely affected usually stop growing around eight years old the final height may be between 90cm and 120cm.
- The height of children with a more attenuated form of the disease may not be as severely affected and they can reach around 150cm.

## Facial features

- Very short neck
- Bridge of the nose is flattened
- Wider mouth with an enlarged tongue
- Teeth can be widely spaced and poorly formed with fragile enamel
- Chin may be prominent with a square jaw

People with MPS VII usually have a prominent lower face

The short stature is usually not in proportion; the trunk is relatively shorter than the legs

# Heart

**Slow and progressive valvular heart disease may develop without any obvious clinical effects.** The heart valves are designed to close tightly as blood passes from one chamber of the heart to another in order to stop the blood flowing back in the wrong direction. Heart murmurs will occur if the valves become damaged by stored mucopolysaccharides.

## Testing and management

An **ECG** test to measure the electronic activity of the heart, and an echocardiogram (ultrasound scan), are used to identify problems with heart muscle, function and valves. It is a painless procedure and is often carried out annually (or as often as your doctor thinks necessary) to show whether any problems are starting. An operation may be needed to replace damaged valves.

An **electrocardiogram (ECG)** is a test which measures the electrical activity of the heart

# Lungs and breathing

Many people with MPS VII can struggle to maintain an open airway due to the narrowing of the airways and GAG deposits, which leads to breathing difficulties.

In older teenagers and adults, the heart and lungs are squashed within a smaller area, making coping with chest infections harder. It is important to discuss any respiratory or breathing difficulties with your doctor so that the right treatment can be prescribed.

Bacterial chest infections can be treated with antibiotics

## Symptoms

- Upper and lower respiratory infections
- Sleep apnoea, when breathing stops and starts during sleep
- Trouble breathing

## Testing and management

Testing is done via overnight sleep studies. Regular reviews by a respiratory and ENT specialist can ensure that any necessary respiratory support is given. Some may benefit from the use of nebulisers and inhalers or an overnight **continuous positive airway pressure** (CPAP) or **bilevel positive airway pressure** (BiPAP), which pump air into the airway. Enlarged tonsils and adenoids may be removed to relieve upper airway obstruction and sleep apnoea.

Ear, nose, and throat (ENT) is a medical specialism



# Liver, spleen and intestines

The liver and spleen are organs within the tummy (abdominal) area of the body. This area can look prominent for some people as the organs become enlarged.

## Liver and spleen

The liver performs important tasks; it filters blood, produces a digestive liquid called bile to aid digestion, and stores energy. The spleen supports the immune system to help the body fight infections. An **enlarged liver and spleen** can develop from the build-up of mucopolysaccharide deposits (GAGs). Although these organs can continue to function normally, the abdomen may be distended and the pressure may affect eating and breathing.

An enlarged liver and spleen is known as **hepatosplenomegaly (HSM)**



## Intestines

Occasionally, with a young child, diarrhoea can be present on its own or caused by severe constipation through leakage of loose stools from behind the solid mass of faeces. The problem may resolve itself as the child gets older, but it can be worsened by antibiotics prescribed for other problems. Constipation may become a problem as a child gets older as they may become less active and the muscles weaken.

Hernias are commonly seen in people with MPS VII. This happens when an organ, such as the intestine, pushes through a weak spot in the muscle that holds it in place.

Depending on the type of hernia, surgery is sometimes needed



When making changes to your diet to improve digestive issues, make just one change at a time so you can see what is helping

### Digestive issues

These issues are caused by enlarged organs. The rib cage restricts the stomach which means that people with MPS VII may need to eat little and often, and may vomit due to the pressure. Weight gain is also an issue for this group as they become less active and less mobile, so it is important to maintain a good balanced diet.

### Symptoms

- Feeling sick, bloated, or vomiting after a meal
- Stomach cramps
- Changes in weight

### Management

- Eating smaller meals at more regular intervals
- Sitting up straight while eating and taking small mouthfuls
- Avoiding spicy, high-fat foods and acidic foods
- Avoiding excesses of alcohol and caffeine
- Taking regular, gentle exercise
- Drinking plenty of water
- Gradually increasing fibre intake if constipated, or eating less if experiencing diarrhoea

## Eyes

Changes to the eyes are nearly always present and one common symptom is corneal clouding, which occurs when the cornea becomes scarred and stops light from passing through to the retina. The cornea may appear white or clouded. In early stages it does not generally impair or affect sight. It can be detected by eyecare professionals and provide an early sign that should be investigated before a diagnosis is made.

Changes to the eyes are known as **ophthalmological** changes

## Ears

Some degree of deafness is common. It may be conductive deafness, nerve deafness or both, called mixed deafness, and can be made worse by frequent ear infections.

**Conductive deafness** is when sound waves that travel through the ear canal, drum and the middle ear are impaired. Glue ear is where the middle ear fills with glue-like fluid instead of air, blocking the transmission of sound waves.

**Nerve deafness** is damage to the tiny hair cells in the inner ear. It may happen at the same time as conductive deafness; in which case it is referred to as **mixed deafness**.

## Dental

Because of potential problems with teeth and their enamel, good dental hygiene is especially important to avoid the need for extractions and other dental treatment. Using electric or battery-operated toothbrushes works better, especially for those with poor hand function.

### Management

- Glue ear can be treated through surgery by inserting grommets into the ear. Small ventilation or tympanostomy tubes (T-tubes) are commonly used.
- Nerve deafness is usually managed by fitting hearing aids.
- Mixed deafness can be managed by grommets (small ventilation or T-tubes) or hearing aids.

The use of radio aids and the loop system can be helpful at school and at home.

## Anaesthesia

When having an operation or procedure that requires an anesthetic, it is important that the patient is seen by an anaesthetist experienced in MPS conditions or difficult airways. Pre-operative assessments should be carried out by those experienced in supporting MPS VII patients and the risks of every surgery explained.

For people with MPS VII, the airway can be very small and placing the tube in position for surgery can prove difficult. The doctor will use a flexible tube with a light and camera on the end in order to place the tube correctly.

This tube is known as an **endotracheal** tube

Equipped with a camera and light this is known as a **bronchoscope**

It is important that attempts are not made to extend the neck, especially when opening the airways. The cervical junction, the area where the skull and upper cervical spine connect, should always be considered unstable until proven otherwise. Attempts to adjust the area may compromise the spinal cord and be life threatening. The anaesthetist will be especially careful when repositioning the neck to avoid injury to the spinal cord.

Make medical staff aware of MPS VII and the anaesthetic risk for surgery and ask them to speak with your specialist team.

## Living with MPS VII Sly

**The MPS Society is able to provide more information on the following:**

- Living independently
- Education and transition to employment
- Holistic approach, including well-being and mental health

Please contact us on **0345 389 9901** or visit our website [mpssociety.org.uk/advocacy](https://mpssociety.org.uk/advocacy) if you would like to find out more about how the MPS Society can support you.

We provide a support network promoting understanding and awareness of the diseases





# Support and Advocacy Lead, Steve Cotterell, shares his story

**I am proud to head up the Support and Advocacy Team. Having worked as a support officer for many years I understand the determination and expertise required to support our families and individuals living with these diseases.**

Supporting children, young people and adults affected by MPS, Fabry and related conditions and their families is at the heart of what we do, and so we strive to provide a responsive service that gives people the help they need when they need it.

We are often able to make a positive difference to the lives of our community and this gives a real sense of achievement.

In particular, the rarity of these conditions means affected individuals and their families often experience difficulties accessing adequate needs-led support and services in their local area. We provide a support network promoting awareness and understanding of the diseases and we work in partnership with you and your family as well as developing professional relationships with local health professionals.

Each of our support officers has specialist knowledge in the particular diseases they look after so if you want to know anything about MPS VII we can help and are here to provide emotional support, practical advice, information and guidance, and signposting where needed.



# What kind of treatments and therapies are available for MPS VII?

Although there is currently no cure, management of MPS VII is outlined on pages 7 to 15 and the doctors will offer a range of treatments depending on the symptoms that the patient experiences. Because symptoms are highly individual, treatment will vary from person to person. Medical companies are looking into treatment of rare diseases and new treatments may become available in the future. Your specialist team will make you aware of any new trials or treatments.

The most common current treatment is enzyme replacement therapy (ERT). This uses a genetically engineered form of the missing or malfunctioning enzyme administered once a week by intravenous infusion over a number of hours. While ERT is available it is not yet commissioned by NHS England.

If you would like more information on treatment options and clinical trials, then please contact your MPS VII specialist or the MPS Society.

More information about treatments is available here: [mpssociety.org.uk/treatments](https://mpssociety.org.uk/treatments) and the latest information about clinical trials can be found here: [mpssociety.org.uk/clinical-research](https://mpssociety.org.uk/clinical-research)



*Because symptoms are highly individual, treatment will vary from person to person*

# Where can I get more information and support?



**The Society for Mucopolysaccharide Diseases (MPS Society) is the only registered UK charity providing professional support to individuals and families affected by MPS and related lysosomal storage diseases throughout the UK.**

Further information booklets and other resources about MPS, Fabry and related diseases are available from [mpssociety.org.uk](http://mpssociety.org.uk)

Our Support and Advocacy team have specialist knowledge of these diseases and a background in social care. We are here for you whenever you need us.

Phone us on **0345 389 9901** Mon to Fri 9am–5pm

Outside these hours you can call us on **07712 653 258**  
Mon to Fri 7am–9am and 5pm–10pm  
Sat and Sun 7am–10pm

Email us at [\*\*advocacy@mpssociety.org.uk\*\*](mailto:advocacy@mpssociety.org.uk)

Members in Northern Ireland can contact our Northern Ireland based advocacy worker on **07786 258 336**

Every effort has been made to ensure that the information in this booklet was accurate and up to date at the time of going to press. This booklet is not intended as a substitute for professional medical advice and the MPS Society and other contributors cannot take responsibility for actions taken as a result of this information.

## **Society for Mucopolysaccharide Diseases**

MPS House, Repton Place  
White Lion Road, Amersham  
Buckinghamshire, HP7 9LP

**0345 389 9901**

**[mps@mpssociety.org.uk](mailto:mps@mpssociety.org.uk)**

**[mpssociety.org.uk](http://mpssociety.org.uk)**

Registered Charity No. 1143472  
Registered as a Company limited by  
guarantee in England & Wales No. 7726882  
Registered as a Charity in Scotland No. SCO41012

© 2022 Society for Mucopolysaccharide Diseases

**This booklet was written by MPS Society UK with input from clinical specialists.  
Production was supported with funding from Ultragenyx.**